Willow vs RxActivate: oral GLP-1, tracking vs gated pricing
Quick verdict: Willow emphasizes a telehealth-first oral GLP-1 program with progress tracking and follow-up support and lists a starting price of 299, while RxActivate requires an eligibility questionnaire and gates pricing behind contact-information before revealing plan or price.
Explore Willow program details
Willow vs RxActivate: how they differ at a glance
This direct comparison focuses on the clearest distinctions between Willow and RxActivate using only the supplied evidence: pricing disclosure, intake and eligibility flow, follow-up and tracking features, clinician review and regulatory notes, and state availability and gating.
1. Pricing disclosure and transparency
Willow: The captured evidence lists a starting price of 299 and a price detail of 299. RxActivate: Pricing is unverified on the landing page and is gated behind completion of the medical eligibility questionnaire and submission of name, email and phone number. The RxActivate evidence explicitly states no price, medication fee, membership fee, shipping charge, cancellation term or billing commitment was displayed before the contact-information gate. These are direct differences in price visibility.
Start RxActivate eligibility quiz
2. Intake flow and clinician matching
Willow: Described as telehealth-first with a licensed telehealth team and follow-up consultations; treatment is available only when a licensed clinician determines it is medically appropriate. RxActivate: Uses a two-minute eligibility questionnaire to produce clinician-matched GLP-1 plans, with state and medical-safety screening and treatment subject to licensed clinician review. RxActivate explicitly requests personal details after showing likely eligibility before revealing plan or price.
Check Willow clinician process
3. Support, tracking and program framing
Willow frames its offering as a structured weight management journey rather than a medication subscription, emphasizing progress tracking tools and follow-up support to convert GLP-1 efficacy into long-term outcomes. RxActivate emphasizes clinician-matched plans after an eligibility flow; the captured evidence highlights state and medical-safety screening and a clinician review process but does not capture the same progress-tracking framing.
4. Availability and gate behavior
RxActivate evidence confirms Alabama serviceability in a synthetic test and notes the eligibility flow loads correctly. Willow captured page returned an error page on browser verification and readable landing-page evidence was not captured. Where availability detail was supplied, it is present for RxActivate; Willow has no captured availability details beyond telehealth licensing and clinician determination.
5. Regulatory and compounded-medication notes
Both providers’ captured evidence includes the regulatory caution that treatment is available only when a licensed clinician determines it is medically appropriate and that compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. The detail that medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable appears in both records.
Comparison table: Willow vs RxActivate
| Criteria | Willow | RxActivate |
|---|---|---|
| Primary approach | Telehealth-first weight management with progress tracking | Clinician-matched GLP-1 plans after eligibility quiz |
| Pricing disclosure | Starting price listed: 299 | Pricing gated; unverified before contact-information |
| Intake flow | Licensed telehealth team, follow-up consultations | Two-minute eligibility questionnaire; contact gate |
| Tracking and follow-up | Progress tracking tools and structured follow-up | No captured progress-tracking claim in evidence |
| Availability notes | No captured state availability; page returned error | Alabama confirmed serviceable in synthetic test |
| Regulatory note | Treatment subject to clinician review; compounded meds not FDA-reviewed | Treatment subject to clinician review; compounded meds not FDA-reviewed |
Practical takeaways and decision guidance
Willow emphasizes structured digital follow-up and progress tracking, and the captured evidence lists a starting price of 299. RxActivate emphasizes an eligibility flow that matches users to clinician-reviewed plans but requires personal contact information before revealing price or plan details; the flow was confirmed to load and Alabama was serviceable in a test.
Proceed with RxActivate intake
Learn more about Willow enrollment
Choose Provider guidance
- Choose Willow if you want a telehealth-first oral GLP-1 program framed as a structured weight management journey with progress tracking tools, follow-up consultations and a listed starting price of 299.
- Choose RxActivate if you prefer a clinician-matched GLP-1 plan and are prepared to complete a two-minute eligibility questionnaire and provide contact information to see pricing, noting that Alabama availability was confirmed in a synthetic test.